Back to Search

Eli Lilly and Co

LLY

Pharmaceuticals • Pharmaceuticals

$1231.94
+46.23 (+3.90%)

Market Cap: $1116.2B

Price Chart

5/10

criteria met

Verdict

Overvalued

Eli Lilly and Co (LLY) meets 5 of 10 fundamental criteria on Stoxly's checklist. The fundamentals may be sound, but the current valuation looks stretched. The P/E or PEG ratio suggests the price has outpaced financial performance.

For educational purposes only — not financial advice. Data may be delayed.

Valuation

Is the stock reasonably priced for what you get?

P/E Ratio

42.2
Target: < 25 Not met

PEG Ratio

1.5
Target: < 2.0 Criteria met

Price/Book Ratio

38.3
Target: < 3.0 Not met

EV/EBITDA

N/A
Target: < 15Data not available

Growth & Profitability

How fast is the business growing and how efficiently does it earn money?

Revenue Growth

31.7%
Target: > 10% Criteria met

ROE

77.8%
Target: > 5% Criteria met

Operating Margin

40.4%
Target: > 10% Criteria met

Return on Assets

18.4%
Target: > 5% Criteria met

Financial Health

Can the company comfortably cover its obligations?

Quick Ratio

0.8
Target: > 1.5 Not met

Debt/Equity Ratio

1.6
Target: < 1.0 Not met

Free Cash Flow Yield

N/A
Target: > 0%Data not available

Dividend Yield

0.58%
Informational

Dig deeper before you buy

The research platforms we reach for when a stock passes the first screen:

Some links above are affiliate links — Stoxly may earn a commission if you open an account or subscribe, at no extra cost to you. This never influences analysis results. Affiliate disclosure